# Study of JS004 Combined With Toripalimab for Advanced Lung Cancer

> **NCT05000684** · PHASE1,PHASE2 · COMPLETED · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 67 (actual)

## Conditions studied

- Advanced Lung Cancer

## Interventions

- **DRUG:** JS004 in combination with toripalimab

## Key facts

- **NCT ID:** NCT05000684
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-27
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-10-31
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2025-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05000684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05000684, "Study of JS004 Combined With Toripalimab for Advanced Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05000684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*